In a move to help researchers in the study of the coronavirus, over 2,500 volunteers in the United Kingdom (UK) will participate in the ‘Human Challenge COVID-19 trials’ with each participant receiving £4,000 (around Rs 4 lakh) for their two to three-week stay.
The trials are likely to begin in January 2021 and the initial study will have around 90 volunteers under the age of 30, according to the dailymail.co.uk. They will receive a dose of an experimental nasal vaccine before being deliberately infected with COVID-19.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).